Mesenchymal stem cells treatment for ischemic stroke: an update on animal studies

Abstract

Mesenchymal stem cells (MSCs) have great potential in the treatment of ischemic stroke. Because they possess low immunogenicity, high proliferation, and different capabilities. MSCs are mostly derived from bone marrow, adipose tissue, and placenta; they act mainly by regulating immune and inflammatory responses, neuroprotection, and promoting angiogenesis; they can be introduced into the body via intracerebral or intravascular injection, and their efficacy in treating ischemic stroke can be enhanced when combined with physical methods such as hypoxic pretreatment. This paper reviews the animal studies of MSCs treatment of ischemic stroke and describes the therapeutic effects of MSCs on ischemic stroke model animals from the perspectives of the types of MSCs, mechanisms of action, injection methods, and physical methods of intervention to enhance the efficacy of MSCs, to provide new ideas for the clinical treatment of ischemic stroke.

doi：10.3969/j.issn.1672⁃6731.2023.04.017